alexa MicroRNAs: Decoders of Dysbiosis into Metabolic Diseases? | OMICS International
ISSN: 2155-6156
Journal of Diabetes & Metabolism
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

MicroRNAs: Decoders of Dysbiosis into Metabolic Diseases?

Matteo Serino1,2*

1Institute of National Health and Medical Research (INSERM), Toulouse, France

2University Paul Sabatier (UPS), Mixed Research Unit (UMR) 1220, Institute for Research in Digestive Health (RDC), CHU Purpan, Instead of Doctor Baylac, CS 60039,

31024 Toulouse Cedex 3, France

*Corresponding Author:
Matteo Serino
Institute of National Health and Medical Research (INSERM)
Toulouse, France; University Paul Sabatier (UPS), Mixed Research Unit (UMR) 1220
Institute for Research in Digestive Health (RDC), CHU Purpan, Instead of Doctor Baylac
CS 60039, 31024 Toulouse Cedex 3, France
Tel: +33562744525
E-mail: [email protected]

Received date: July 20, 2016; Accepted date: Aug 28, 2016; Published date: Sep 05, 2016

Citation: Serino M (2016) MicroRNAs: Decoders of Dysbiosis into Metabolic Diseases?. J Diabetes Metab 7:698. doi: 10.4172/2155-6156.1000698

Copyright: © 2016 Serino M, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Diabetes & Metabolism


The identification of molecular factors bridging gut microbiota dysbiosis to alterations of host metabolism still remains a major goal in biomedical research. In fact, on one hand, there is a worldwide consensus about the systemic impact, from brain to liver, from heart to adipose tissue, of gut microbiota dysbiosis. On the other hand, beyond the microbial production of short chain fatty acids and their vast metabolic properties, little is known about the molecular mechanisms linking a change in the activity of gut microbes to a modification of host cell metabolism. In this context, microRNAs (also known as miRs) are promising molecules which could allow explaining how dysbiosis is converted into metabolic outcomes since: 1- miRs are pleiotropic regulators of gene expression, targeting multiple mRNAs at once; 2- miRs expression in specific organs such as the intestine has been demonstrated to be under the control of gut microbiota; 3- alterations in miRs expression have been found in the majority of tissues targeted by gut microbiota dysbiosis during metabolic diseases such as liver, adipose tissue, pancreas, skeletal muscle, intestine, heart and also the brain. In this short review major publications in the growing field of miRs-based metabolic control at a systemic level will be discussed together with a putative link with gut microbiota dysbiosis.


Gut microbiota; Dysbiosis; MicroRNAs; Metabolic diseases; Infections


The discovery of the active role of gut microbiota, the trillions of microorganisms inhabiting the gastrointestinal tract of both humans and animals, on whole host metabolism is radically pushing for a new era in medical development, centred on personalized medicine [1].

Recently, the exponential growth of “newly rediscovered” [2] microbial-based therapies such as fecal microbiota transplantation (FMT) for both Clostridium difficile recurrent infections [3,4] and metabolic syndrome [5] has demonstrated that gut microbiota represents an effective target for the managing of multiple diseases.

The most striking evidence is related to the fact that gut microbes exert a vast range of metabolic functions, beyond digestion. As a consequence, the alteration, named dysbiosis, of this multifaceted microbial system within our intestine affects host pathophysiology at a multi-organ level [6]. Thus, the growing interest in gut microbiota dysbiosis is based on the experimental evidence that both ecological [7] and functional [8] alterations of gut microbes have a systemic impact on whole host metabolism (Figure 1). Indeed, the metabolic influence of dysbiosis is not limited to a specific period of life, but rather it affects lifespan from childhood to adulthood [9].


Figure 1: Systemic metabolic overlap at the organ level between gut microbiota dysbiosis and altered miRs expression. The impact of gut microbiota dysbiosis (i.e. induced by metabolic diseases) on whole host metabolism is as inner as capable to affect host pathophysiology at a multi-organ level. Of note, alterations in miRs expression have been found in several tissues targeted by gut microbiota dysbiosis during metabolic diseases such as liver, white adipose tissue, pancreas, skeletal muscle, heart, intestine and brain. These evidences sustain the hypothesis that miRs may be among the molecular factors converting dysbiosis into dysmetabolism at the level of tissue cell. Major miRs discussed in the main text are reported (in bold are miRs found modulated in humans; the others are related to animals; arrows indicate the modulation of miR expression associated to either a given disease and/or observed or putative gut microbiota dysbiosis and the activation of microbial receptors; red-edged rectangles describe observed or putative gut microbiota dysbiosis associated to the related modulation of miR expression).

Therefore, scientific community is now paying extreme attention to identify the molecular mechanisms by which dysbiosis of gut microbiota alters metabolic pathways of the host. In this context, a huge literature about short chain fatty acids (SCFAs) has flourished in the recent years. In fact, SCFAs, produced by fermentation of complex carbohydrates from plants, have been shown effective in the regulation of crucial functions of the host such as inflammatory response [10], incretins-based control of glucose-tolerance [11] as well as adiposity and energy balance [12], to cite a few. However, when descending at the molecular level of bacteria-to-cell interaction, our knowledge of the complex bidirectional relationship between gut microbiota and the host still has to face its limitations.

Importantly, microRNAs (also miRs) could help deciphering the dialogue between microbes and host cells. Since their discovery in 1993 [13], miRs have held the attention of researchers given their pleiotropic abundance, ranging from plants to animals, and their capacity to regulate gene expression [14]. These tiny molecules of about 22 nucleotides in length belong to the subfamily of small noncoding RNAs such as tRNAs, rRNAs and many others [15], which has to be distinguished from the subfamily of long non-coding RNAs (lncRNAs), longer than 200 nucleotides and without a protein-coding sequence [16]. MicroRNAs are very stable, proposing them as excellent biomarkers for cancer [17] and other diseases such as type 2 diabetes [18]. Of note, a vast range of metabolic pathologies is characterised by alterations in miRs expression in both central and peripheral organs (Figure 1). In this short review these alterations will be discussed in both humans and animals and analysed in parallel with gut microbiota dysbiosis associated to pathophysiological modifications in these organs (Table 1).

Organ miR modulation Text reference Associated dysbiosis/microbial receptor activation
Liver ↑miR-103, ↑miR-107 27 ↑ Firmicutes
↑ Porphyromonadaceae
↑ Erysipelotrichi
↑miR-143, ↑miR-145 28
↑miR-21 30, 31, 32
White adipose tissue ↓miR-193b 26 ↑ Firmicutes
↑miR-103, ↑miR-107 27
↑miR-21 30, 31, 32
Pancreas ↓Chr 14q32 miRs cluster 40 NOD1, TLR-4, TLR-7
↓miR-375 41,42
↑miR-34a, ↑miR-124a, ↑miR-383, ↓miR-130b, ↓miR-181a 43
Heart ↑miR-24, miR-125b, ↑miR-195, ↑miR-199a, ↑miR-214 54 ↑ Prevotella
↑ Proteobacteria,
↓ Bifidobacteria
↑miR-100 55
↑miR-208a 62
Skeletal muscle ↓ miR-194 64 ↑ Bacteroidetes
↓miR-16 65
Brain ↓miR-198 70 ↑ Actinobacteria
↑miR-200a, ↑miR-200b,
Gut ↓miR-193a-3p 82 ↑ Bacteroidaceae
↑ Helicobacteraceae
↓ Prevotellaceae
↓ Porphyromonadaceae
↓ Lachnospiraceae
↓ Ruminococcaceae
↑miR-33a, ↑miR-122 83
↓miR-423-5p 85
↑miR-203, ↑miR-483-3p, ↑miR-595 86

Table 1: Organ-specific miR expression modulation and associated gut microbiota dysbiosis.

Putative microbial miRs regulation in dysmetabolism - Focus on: Hepatic and white adipose tissue miRs

The liver and the white adipose tissue (WAT) are crucial organs for the regulation of glucose homeostasis at a systemic level.

Nowadays, it has been achieved that both organs are targeted by gut microbiota dysbiosis, which can be related to the expansion of the phylum Firmicutesi [7] or the family Porphyromonadaceae [19].

As for the liver, the gut-to-liver axis plays a fundamental role with regard to the capacity of liver to filter xenobiotics and sense microbial products [20]. Recently, an important role of hepatic modulators has been revealed for bile acids [21], also shown able to impact on miRs expression in human hepatocytes [22] and to play as putative therapeutics in non-alcoholic fatty liver disease (NAFLD) [23], a common feature of metabolic diseases. NAFLD is associated with increased abundance of Erysipelotrichi and lower levels of Gammaproteobacteria in human stool [24]. In this context, Leti et al. found 30 up-regulated and 45 down-regulated miRNAs by using highthroughput sequencing to assess miRNAs obtained from liver biopsies of 15 individuals without NAFLD fibrosis (F0) and 15 individuals with severe NAFLD fibrosis or cirrhosis (F3-F4) [25].

As for the human WAT, numerous miRs exist but only a few number is altered in obesity and type 2 diabetes mellitus such as miR-193b, whose expression correlates positively with adiponectin gene expression and negatively with homeostasis model assessment of insulin-resistance [26].

In mice, the up-regulation of miR-103 and miR-107 was observed in obese mice and gain of function of both miRs in the liver and WAT impairs glucose metabolism [27]. By contrast, silencing of miR-103 and miR-107 improves insulin-sensitivity [27]. The expression of two other miRs, miR-143 and miR-145, is increased in the liver of both genetic and nutritional murine models of obesity [28].

These two miRs act like a cluster, therefore, mice deficient for both miR-143 and miR-145 are protected from obesity-related comorbidities such as insulin-resistance. However, only the overexpression of miR-143, but not that of miR-145, is able to impair AKT-mediated insulin-signalling and thus glucose homeostasis.

Another important factor regulating adiposity and hepatic metabolism is miR-21, known as a disease-linked miR [29]. The team of Prof. Dimmeler recently showed that the long-term (18 weeks) inhibition of miR-21 is effective to reduce body weight and adipocyte size in aged db/db mice [30], whereas in the liver miR-21 regulates both regeneration [31] and progression of fibrosis [32]. With regard to the impact of miRs expression on hepatic metabolism also contradictory results can be found. In fact, it has been shown that the hepatocyte-specific deletion of the miR-processing enzyme Dicer1 has either no impact on the hepatic function [33] or promotes hepatocarcinogenesis in mice [34]. Indeed, both liver [19,35,36] and adipose tissue [37-39] have been shown to be specifically and deeply targeted by dysbiosis of gut microbiota, as reported above.

These evidences strongly suggest the association between a change in miRs expression and the impact of gut microbiota dysbiosis for the control of both hepatic and WAT metabolism.

Pancreatic miRs

Interestingly, alterations of miRs expression can also be found at the level of the pancreas, a crucial organ exerting the maintenance of glucose homeostasis by secreting insulin and glucagon.

In humans, Kameswaran et al. described a cluster of miRs in an imprinted locus on human chromosome 14q32. This locus is highly and specifically expressed in human beta-cells and is intensely downregulated in islets from diabetic donors [40].

In mice, the high expression of miR-375 was shown important for the normal pancreatic alpha- and beta-cells mass [41] as well as for the regulation of insulin secretion [42]. Moreover, an ageing-associated upregulation of miR-34a, miR-124a and miR-383, and downregulation of miR-130b and miR-181a were found in the pancreas of 12-monthold rats [43]. Importantly, besides the well-established age-induced modification of gut microbiota [44], clear evidences between the link of pancreas health and sensing of microbial antigens have been provided by several publications. In fact, in this context, the NOD1- mediated experimental pancreatitis [45], the impact of TLR-4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice [46] as well as the impact of TLR-7 on pancreatic carcinogenesis both in humans and mice [47] have been demonstrated. Thus, it appears clear that a dysbiosis-induced altered production of multiple microbial antigens such as peptides derived from bacterial cell wall and containing for instance D-glutamyl-meso-diaminopimelic acid (iEDAP) moiety (recognized by NOD1), lipopolysaccharides (LPS, recognized by TLR-4) and single-stranded microbial RNA (recognized by TLR-7) may drive pancreatitis.

Again, these evidences converge towards the association between altered miRs expression and gut microbiota dysbiosis on pancreatic functions.

Cardiac miRs

Recently, the microbial activity has been shown effective in promoting cardiovascular diseases via a mechanism based on the metabolism of phosphatidylcholine [48]. Nevertheless, contrasting results can be found in the literature with regard to the metabolic impact of microbial-generated metabolites from phosphatidylcholine, such as trimethylamine (TMA) and TMA-N-oxide (TMAO) [49]. In detail, regarding the human enterotype classification [50], the enterotype Prevotella is associated with higher blood levels of TMAO than the enterotype Bacteroides in humans [51]. With regard to the cardiac metabolism in a context of gut microbiota dysbiosis, we showed that the severity of cardiac metabolism in a murine model of metabolic adaptation to a high-fat diet [52] is associated to a specific periodontal microbiota characterized by a 37% abundance of Proteobacteria [53]. Thus, these data suggest a link between periodontal microbial activity and heart pathophysiology.

With regard to cardiac miRs, in humans, an altered expression has been found for mir-24, miR-125b, miR- 195, miR-199a and miR-214 in the human left ventricle when comparing samples from control and ischemic cardiomyopathy, dilated cardiomyopathy or aortic stenosis groups [54]. Matkovich et al. also reported, by microarray profiling of miRs, an upregulation for mir-100 and miR-195 in human heart tissues (myocardial specimens) in clinical and experimental congestive heart failure (CHF) [55]. Of note, all the above reported cardiovascular diseases are strongly associated with metabolic diseases, as well known.

Recently, soluble ST2 (suppression of tumorigenicity 2) has emerged as novel cardiac bio-marker, especially in heart failure and ischemic heart diseases [56]. Soluble ST2 is a blood protein which acts as a decoy receptor for IL-33, limiting IL-33 interaction with ST2 ligand [57]. Notably, the induction of IL-33 by the gut microbiota has been recently shown in a model of inflammatory bowel diseases [58], characterized by several dysbioses such as a Bifidobacteria decrease [59] or an increase in Proteobacteria [60]. Finally, Xiang et al. published that miR-487b acts as a negative regulator of macrophages activation by targeting IL-33 production [61]. Thus, these experimental evidences show the inner link between gut microbiota and the regulation of miRs expression for the control of pathophysiological manifestations.

Importantly, considering that dysbiosis has been primary identified and extensively studied in diabetes and obesity, strong risk factors for cardiovascular diseases, and taking into account the role of gut microbiota in the modulation of energetic metabolism [37], the work from Grueter et al. suggests a bridge between gut microbiota dysbiosis and cardiac metabolism via miRs expression. In fact, the authors found that a cardiac-specific microRNA, miR-208a, is able to negatively regulate MED13, a subunit of the Mediator complex, resulting in diminished energy expenditure [62]. Altogether, these experimental evidences propose that an altered miRs expression and gut microbiota dysbiosis meet to manage the pathophysiological status of a given organ.

Skeletal muscle and miRs

Among the main effects of gut microbiota on whole host physiology is the up-regulation of the energetic metabolism. In fact, Backhed et al. showed that the resistance of axenic mice to diet-induced obesity is associated with hepatic and skeletal muscle increased levels of phosphorylated energetic intracellular sensor AMP-activated protein kinase (AMPK) and its downstream targets Acetyl-CoA carboxylase and Carnitine-palmitoyltransferase, positive regulators of fatty acid oxidation [38]. Thus, this work firstly provided the existence of a gutto- skeletal muscle axis. A vast body of evidences in the scientific literature shows the relationship between metabolic diseases and altered muscle metabolism. For instance, Kase et al. showed that myotubes from obese/diabetic patients had lower lipolysis (-30%/-40%) when compared to lean subjects, together with a lower insulin-stimulated glycogen synthesis (-60%) and AKT phosphorylation (-90%) [63]. In this context, it has been recently shown that Type 2 Diabetes mellitus is associated with regulation of several miRs in the skeletal muscle. Latouche et al. identified miR-194 as the sole miR whose expression was reduced across different phases of the disease progression, from an early insulin-resistance to the establishment of diabetes [64]. In Zucker rats, Lee et al. found almost a 50% reduction in the expression of miR-16, controlling the accretion of skeletal muscle protein, during insulin-resistance, when compared to lean rats [65].

Importantly, in the absence of obesity, both T2D patients [66] and mice [52] display a dysbiosis dominated by the phylum Bacteroidetes, which therefore is in association with the above reported miRs profiling.

Brain and miRs

According to note, beyond peripheral organs, also the brain is affected by miRs alterations. Moreover, gut microbiota has been shown to correlate to and affect both cerebral structure and behaviour in humans, where the phylum Actinobacteria was associated with functions of the thalamus, hypothalamus and amygdala [67] and mice [68,69]. In humans, there is a rich literature regarding the role of miRs in human glioma. For instance, Man et al. found a significant downregulation of miR-198 expression in 122 pairs of human gliomas compared with corresponding non-neoplastic brain tissues. Also reduced levels of miR-198 were associated with a higher WHO grade and lower Karnofsky performance status (KPS) score. Finally, overexpression of miR- 198 in U87 cells reduced cell proliferation, increased cell apoptosis and repressed both cell invasion and migration [70]. Altogether, these data suggest that miR-198 may act as a tumor suppressor, proposing miR-198 as a new target for molecular therapies in human glioma and opening the route towards the study of gut microbiota dysbiosis in this disease.

Importantly, the energetic metabolism can bridge the above reported pathology with both metabolic effects and gut microbial activity. In fact, Adeberg et al. reported that metformin is associated with prolonged progression-free survival in diabetic glioblastoma patients [71]. Notably, numerous experimental evidences link the metabolic effects of metformin with gut microbial modulation in both humans, where metformin increased the abundance in Escherichia spp. and lowered Intestinibacter in T2D [72] and animals, such as Caenorhabditis elegans , by altering folate metabolism and methionine cycle of E. coli [73]. Finally, metformin was shown effective in targeting miRs expression in diabetic subjects [74], closing the circle between brain, metformin, gut microbes and miRs.

In animals, miR-200a, miR-200b and miR-429 are up-regulated in the hypothalamus of ob/ob mice. A leptin treatment is able to downregulate the expression of these miRs and the silencing of miR-200a is effective against body weight gain, restoring hepatic insulin-sensitivity [75]. The team of Pettersson was the first to show that a normal gut microbiota is able to modulate both brain development and behaviour [69]. Subsequently, Hsiao et al. published an elegant work showing that gut microbiota is able to modulate behavioural and physiological abnormalities associated with neurodevelopmental disorders in the field of autism [76]. Importantly, obese-type dysbiosis is able to induce neurobehavioral changes even regardless of the driver pathology, as observed for obesity [77]. Recently, Braniste et al. published that gut microbiota influences the permeability of blood-brain barrier in mice [68], showing that both intestinal [78] and central permeability are under the control of gut microbes. Therefore, to the light of the aforementioned evidences, it appears likely that a link may exist between gut microbiota and miRs, two main modulators of brain function.

Gut microbiota and miRs modulation: From association to causality?

The work from Dalmasso et al. provided a first experimental proof for a direct link between gut microbiota and the regulation of miRs expression. In fact, by comparing axenic vs. conventionalized mice, the authors showed that both in the ileum and the colon the expression of specific miRs was under the control of gut microbiota [79]. Still focusing on intestinal miRs, Liu et al. demonstrated that gut miRs synthesis from the host is effective in regulating gut microbiota dysbiosis. The authors developed a mouse model with no mature miRs all along the intestinal tract, by using a gut-specific deletion of Dicer1, the miR-processing enzyme, already mentioned above [33,34]. As a consequence, these mice had no fecal miRs and developed exacerbated dextran sulfate sodium (DSS)-induced colitis, displaying gut microbiota dysbiosis with increased Bacteroidaceae and Helicobacteraceae and decreased Prevotellaceae, Porphyromonadaceae, Lachnospiraceae and Ruminococcaceae families [80]. Thus, this work proposes intestinal miRs as important molecules capable to exert a selection pressure on gut microbiota ecology, limiting uncontrolled microbial overt-abundance and hence gut microbiota dysbiosis. This latter property appears to be based on the capacity of miRs to enter bacteria and directly impact on microbial metabolism. In accordance with the aforementioned work Singh and colleagues found that caecal miRs profile depends on the presence of the endogenous gut microbiota in mice [81].

To sustain the evidence that gut microbiota may impact on host pathophysiology based on a change on miRs profile, Dai et al. recently published that miR-193a-3p is able to reduce colonic inflammation in response to gut microbiota via a down-regulation of PepT1, a di/ tripeptide transporter that uptakes bacterial product [82]. Moreover, Baselga-Escudero et al. reported normalized liver miR-33a and miR-122 levels in high-fat diet-induced obese rats treated with a low dose of proanthocyanidins [83]. These compounds are the most abundant flavonoids in the human diet, and their beneficial effect may rely on the microbial catabolism leading to the subsequent release of absorbable metabolites [84].

The modulation of miRs expression can also be one of the putative mechanisms of action of probiotics, as proposed by Kreuzer-Redmer et al. The authors analyzed the expression of both miRs and their potential target genes in the jejunum and ileum from Enterococcus faecium NCIMB 10415-fed piglets versus untreated controls. The main datum reveals a 2.11-fold increase of miRNA-423-5p and the related downregulation of the immune-relevant immunoglobulin lambda light C region (IGLC) and immunoglobulin kappa constant (IGKC) target genes [85]. On the same direction, Veltman et al. profiled miRs from T84 monolayers before and after co-incubation with E. coli Nissle 1917. The author revealed for the first time miRs differentially regulated such as miR-203, miR-483-3p and miR-595 targeting tight junction proteins [86]. Of note, inhibition of these miRs blunted the disruption of tight junctions induced by enteropathogenic E. coli (EPEC). Thus, the important message of this work is that the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells may be recapitulated by the action of these specific miRs on T84 cells.

Conclusion and Future Directions

The experimental evidences underlined in this short review strongly push to join dysbiosis and modulation of miRs expression for the control of systemic metabolism.

The discovery of the molecular basis underlying the link between gut microbiota dysbiosis and the modulation of whole host metabolism may have a huge impact on the management of the pandemic of metabolic diseases. Furthermore, the microbial universe within the intestine appears to hide a molecular microcosmos inside, since it has been observed that also bacteria can synthesize miRs [87]. Indeed, microbial miRs seem to have broader functions than eukaryotic ones, since they can promote both degradation and stabilization of the targeted mRNAs, such as GadY, a small (59 to 105 nucleotides) RNA regulating acid response genes in E. coli [88].

Thus, deciphering the molecular dialogue between microbes and host may provide innovative targets allowing new therapy to be developed. To the light of this hope, miRs represent promising molecules which may link the intricacy of gut microbial ecosystem to systemic metabolic outcomes arising from gut microbiota dysbiosis. To shed light into this path, more studies are needed to finally validate the direct link between a change in gut microbial ecology and the concomitant modulation of tissue miRs expression for the control of host pathophysiology.


Thanks to Dr. François Tercé and Dr. Vincent Blasco-Baque for critical reading of the manuscript and comments on figure.

Competing Interest

No competing interest exists.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference on Internal Medicine May 21-22, 2018 Osaka, Japan
    May 21-22, 2018 Osaka, Japan
  • International conference on Fitness and Expo June 04-05, 2018 Baltimore, Maryland, USA
    June 4-5, 2018 Baltimore, USA
  • Annual Congress on Research and Innovations in Medicine July 02-03, 2018 Bangkok, Thailand
    July 02-03, 2018 Bangkok, Thailand
  • International Conference on Medical and Health Science August 24-25, 2018 Tokyo, JAPAN
    August 24-25, 2018 Tokyo, Japan

Article Usage

  • Total views: 8864
  • [From(publication date):
    September-2016 - Apr 25, 2018]
  • Breakdown by view type
  • HTML page views : 8735
  • PDF downloads : 129

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version